Serum peptide profiles in patients with carcinoid tumors
- 1 July 2003
- journal article
- Published by Elsevier BV in The American Journal of Surgery
- Vol. 186 (1), 28-31
- https://doi.org/10.1016/s0002-9610(03)00115-6
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumorsRegulatory Peptides, 2000
- Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatinRegulatory Peptides, 1999
- Carcinoid TumorsNew England Journal of Medicine, 1999
- Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoidsGut, 1998
- Gastrointestinal carcinoid tumorsDiseases of the Colon & Rectum, 1997
- Carcinoid diseaseDiseases of the Colon & Rectum, 1997
- Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumoursJournal of Endocrinology, 1995
- Peptide Hormones as Tumor Markers in Neuroendocrine Gastrointestinal TumorsActa Oncologica, 1991
- Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patientsJournal of Internal Medicine, 1990
- Role of neuropeptides and serotonin in the diagnosis of carcinoid tumorsAmerican Journal Of Medicine, 1986